Here you will find the Funding Position of CCG Commissioned High-Cost Drugs within the Lancashire and South Cumbria Health Economy
A number of High-Cost Drugs, devices, procedures and products have been excluded from the scope of the national tariff of Payment by Results. These are listed on tab 13b of the following document:
2024/25 Annex A: The national tariff workbook
High-cost drugs are commissioned by:
The funding position of medicines directly commissioned by NHS England can be accessed via the NHS England website
Refer to the Manual for Prescribed Specialised Services for further information about prescribed specialised services, some of which are directly commissioned by NHS England and some by CCGs.
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 01 - Sep - 2017
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 18 - Oct - 2022
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 18 - Aug - 2020
Approval Mechanism: Prior Approval BLUETEQ form Available
Dibotermin alfa is recommended in Lancashire and South Cumbria for the treatment of acute tibia grade IIIB fractures in adults (as assessed on the Gustilo-Anderson scale), as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation in hospital settings.
Date Posted: 18 - Aug - 2020
Approval Mechanism: Prior Approval BLUETEQ form Available
Dibotermin alfa is not recommended in Lancashire and South Cumbria for use outside of the licensed indication for the treatment of non-union long bone fractures
Date Posted: 01 - Mar - 2014
Approval Mechanism: Group Approval
Date Posted: 01 - Sep - 2018
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 04 - Jun - 2024
Approval Mechanism:
Date Posted: 01 - Nov - 2018
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 01 - May - 2014
Approval Mechanism: Group Approval
Treatment of Thrombocytopenia in adults with Hepatitis C
Date Posted: 27 - Apr - 2023
Approval Mechanism: Blueteq
Date Posted: 08 - Apr - 2021
Approval Mechanism: Prior Approval Blueteq Form Available
Date Posted: 01 - Feb - 2016
Approval Mechanism: Prior Approval Blueteq Form Available
Rheumatoid arthritis (LSCMMG pathway)
Date Posted: 01 - Jun - 2015
Approval Mechanism: Prior Approval BLUETEQ form Available
Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis NICE TA373
Date Posted: 01 - Nov - 2014
Approval Mechanism: Prior Approval BLUETEQ form Available
Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 01 - May - 2013
Approval Mechanism: Prior Approval BLUETEQ form
Date Posted: 01 - Mar - 2016
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 01 - Mar - 2016
Approval Mechanism: Prior Approval BLUETEQ form Available
Date Posted: 04 - Jun - 2024
Approval Mechanism: Blueteq
